Anti-angiogenesis and metastasis: a tumour and stromal cell alliance (Q26862741)

Journal of Internal Medicine

published in

1 reference

volume

273

1 reference

issue

2

1 reference

page(s)

128-37

1 reference

VEGF as a key mediator of angiogenesis in cancer

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Pericytes: gatekeepers in tumour cell metastasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Pericytes limit tumor cell metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Mechanisms of resistance to antiangiogenesis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Anticancer strategies involving the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Hypoxia and hypoxia-inducible factors: master regulators of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Hypoxia generates a more invasive phenotype of tumour cells: an in vivo experimental setup based on the chorioallantoic membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

MET receptor tyrosine kinase as a therapeutic anticancer target

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Tumour-cell invasion and migration: diversity and escape mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Mechanisms of collective cell migration at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Cancer invasion and the microenvironment: plasticity and reciprocity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Cancer dissemination--lessons from leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Microenvironmental regulation of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Inflammation-mediated promotion of invasion and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Endothelial cells form a phalanx to block tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

The hypoxic response of tumors is dependent on their microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Double target for tumor mass destruction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

The clinical implications of the genetics of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Fas/Fas ligand interaction in human colorectal hepatic metastases: A mechanism of hepatocyte destruction to facilitate local tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Antiangiogenic therapies for high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Is the postprogression survival time really not shortened in the bevacizumab-containing arms of phase III clinical trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018

Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12018